INTRODUCTION
Cognitive defi cits are an important cause of functional impairment in Parkinson's disease patients without dementia (PD), and may be apparent early in the disease process (Dubois & Pillon, 1997 ; Levin & Katzen, 1995 ; Owen, 2004 ; Pillon, Boller, Levy, & Dubois, 2001 ; Taylor & Saint-Cyr, 1995 ; Zgaljardic, Borod, Foldi, & Mattis, 2003 ) . Decline in cognitive functioning is associated with caregiver distress (McKinlay, et al., 2008a ; Schrag, Jahanshahi, & Quinn, 2000 ) and early rest home placement, and may also predict the onset of dementia (Jacobs et al., 1995 ; Janvin, Aarsland, & Larsen, 2005 ; Woods & Troster, 2003 ) . Given the relative importance of cognitive impairments, there has been considerable interest in identifying a specifi c cognitive profi le for patients with PD to inform appropriate intervention strategies. and monitor goal-directed behavior, with the fl exibility to update goals when presented with new information. Problems in this area are thought to refl ect fronto-striatal disruption caused by dopamine denervation of the caudate nucleus (Cools, Stefanova, Barker, Robbins, & Owen, 2002 ; Marie et al., 1999 ) .
Given the neuropathology of PD, it has been suggested that the magnitude of any cognitive defi cits will refl ect the degree to which the task relies on the integrity of the frontal executive system (Taylor & Saint-Cyr, 1995 ; Troster & Fields, 1995 ) , and support for this position is emerging. For example, Zamarian and colleagues (2006) examined the performance of 15 PD patients compared to 28 health, age, and education matched controls on measures of executive functioning and numerical ability. They found that PD patients performed worse than healthy controls, but that defi cits in numerical ability were secondary to defi cits in executive functions. Higginson and colleagues ( 2003 ) assessed 32 nondemented PD patients on different aspects of executive function, verbal memory tasks, and disease-related variables to predict performance on delayed recall. Results showed that working memory was the best predictor of verbal recall, accounting for almost 50% of the variance (Higginson et al., 2003 ) . Bondi and colleagues ( 1993 ) examined the performance of 19 PD patients compared to 19 healthy controls on measures of executive functioning, memory, and visuoperceptual/ visuoconstructive skills. Patients showed evidence of defi cits in all areas of cognition tested. However, impairments on tasks of learning and memory and visuoperceptual/visuoconstructive tasks were not signifi cantly impaired when performance on executive function tasks were controlled for. Results from these studies support the idea that subcomponents of executive functions underlie defi cits in other areas of cognitive functioning. However, as noted by Higginson and colleagues (Higginson et al., 2003 ) , there is still some uncertainty regarding the effect of executive defi cits on other areas of cognitive functioning, such as visuoperceptual judgment, which requires further investigation.
There were two primary objectives in the present study. First, we planned to identify a pattern of defi cits in executive functions and general cognitive defi cits for PD patients without dementia using a comprehensive set of commonly used neuropsychological tests. Domains and tests were selected to be consistent with previous research on cognitive defi cits in PD (e.g., Muslimovic et al., 2005 ) . Our second goal was to examine the relationship between different domains of executive function and other areas of more general cognitive function, including memory and visuoperceptual functioning.
METHODS
This study was part of a broader project examining cognitive, neuropsychiatric, and language outcomes for patients with PD, and received approval from the Upper South B Regional Ethics Committee. Assessments were carried out at the University of Canterbury over three testing sessions, each of three hours duration. Tests were presented in a fi xed order with breaks taken as required. Written consent was obtained from all participants at the start of the fi rst testing session, after the study had been explained. Additional in formation pertinent to the inclusion/exclusion criteria (see Table 1 ) was obtained from all participants using a semi-structured interview. Motor impairment was also assessed in PD patients.
Participants

Parkinson's disease group
Parkinson's disease patients in the Canterbury region, identifi ed at the time of this study and not diagnosed with dementia, were invited by letter to participate by two consulting neurologists who specialized in movement disorders. Participants were required to meet the inclusion/exclusion criteria outlined in Table 1 . Of the 115 letters that were mailed, 6/115 (5.2%) of individuals with PD could not participate due to illness, 6/115 (5.2%) were deceased, 8/115 (6.9%) declined, 34/115 (29.6%) did not respond. Of the 61 patients that were tested, 21/115 (18.3%) did not meet the inclusion/exclusion criteria, leaving 40 participants with PD included in the analyses. All patients were tested while on anti-parkinsonian medication (24/40 of the patients were on L-dopa; 20/40 on anticholinergics; 19/40 on dopamine agonists; 14/40 on MAO-B Inhibitor, and 4/40 on COMT Inhibitor). • Diagnosis of idiopathic Parkinson's disease, assessed as between Hoehn & Yahr stages I-IV (stage 1, n = 8; stage 1.5, n = 6; stage 2, n = 7; stage 2.5, n = 10; stage 3, n = 8; stage 4, n = 2).
• Aged between 50-80 years, English as the primary spoken language, adequate or corrected hearing and vision (self-report checked by examiner). Exclusion criteria:
• History of moderate or severe head injury, stroke, or other neurological impairment, major medical illness, or psychiatric illness requiring hospitalization.
• Currently involved in a therapeutic trial.
• Suspicion of dementia (MMSE < 25), diagnosis of learning disability, premorbid IQ < 85 (NART).
• Acute depression (BDI > 16) or major depressive episode in the previous six months.
• Taking other then anti-Parkinsonian medication known to have a signifi cant effect on the central nervous system.
Control group
Forty healthy controls were recruited who were similar to the PD group in terms of age and premorbid intelligence. The control group was recruited from a number of sources, including a previously established database and advertisements at local clubs and businesses. All individuals in the control group were given a brief outline of the study on fi rst phone contact, and, if willing to participate, were sent an information sheet. In addition to adequate or corrected hearing and vision and being between 50 to 80 years of age, the same exclusion criteria listed Table 1 also applied to the control group.
Measures
Demographic and clinical information
The National Adult Reading Test (NART) (Lezak, 1995 ) was used as a measure of premorbid IQ; the Beck Depression Inventory (BDI-II) was used to assess mood and consists of 21 items; each question was rated 0-3, with higher scores indicating greater intensity of symptoms (Beck, Steer, & Brown, 1996 ) . Current mental status was assessed using the Mini-Mental Status Exam (MMSE) (Folstein, Folstein, & McHugh, 1975 ) and the Dementia Rating Scale (DRS-II) (Jurica, Leitten, & Mattis, 2001 ) . In addition to the Hoehn and Yahr (H & Y) (Hoehn & Yahr, 1967 ) , the Unifi ed Parkinson's Disease Rating Scale-motor section (UPDRS) was used to assess the severity of motor symptoms (Fahn & Elton, 1987 ) . A global measure of functional status was obtained using the Modifi ed Schwab and England Activities of Daily Living Scale (S & E; on this scale 0% represents a vegetative state and 100% represents total independence). All the patients rated themselves as independent in daily activities, as rated by the S & E.
Comparisons between patients with PD and Controls are shown in Table 2 . Although there were signifi cant differences between the two groups in terms of current mental status (MMSE) and mood ratings, none of the participants showed any evidence of clinical depression or dementia, as assessed by a registered clinical psychologist using the Diagnostic and Statistical Manual-Fourth edition (DSM-IV) criteria. There were signifi cantly more males in the PD group, PD 26/40 (65%) than in the Control group, 14/40 (35%), χ 2 ( df = 1) = 8.46, p < .01.
Neuropsychological assessment
Neuropsychological assessment covered six cognitive domains: (1) executive function/planning; (2) problem solving; (3) working memory/attention; (4) speed of processing; (5) memory/learning; (6) visuospatial ability. Planning, problem solving, and working memory are considered to be subcomponents of executive function, and were measured separately to examine the different aspects of executive function that might be impaired (Salthouse, 2005 ) . Also included were measures of attention and speed of processing. Although not generally considered subcomponents of executive function, the integrity of these processes is directly linked with efficient processing of executive and general cognitive tasks.
All tests were commonly used neuropsychological measures and scored according to standard procedures. The majority of measures were from standardized batteries with ageadjusted norms, including: Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999 ; mean = 50, SD = 10), Delis Kaplan Executive Function System (D-KEFS; Delis, Kaplan, & Kramer, 2001 ) , and the Wechsler Memory Scale-III (WMS-III Wechsler, 1997 ) , both with mean = 10, SD = 3. Norms were not available for the Behavioral Assessment of the Dysexecutive Syndrome (BADS; Wilson, Alderman, Burgess, Emslie, & Evan, 1996 ) , scores range from 0-4, Cambridge Neuropsychological Test Automated Battery (CANTAB), Reading Span task, and tests of visuospatial functioning. However, PD patients were comparable to Controls in terms age. Executive function/planning skills. These skills were evaluated using the D-KEFS Verbal Fluency test (involving three subtests designed to measure speed and ease of verbal speech) and Color-Word Interference tests (involving two subtests that measure the ability to inhibit automatic verbal responses), and two of the Card Sorting subtests (free sorting and sorting recognition). Also included in this domain were the Intradimensional/Extradimensional Shift (ID/ED) from the CANTAB, which is conceptually similar to the Wisconsin Card Sorting tests and assesses the individuals' ability to maintain and switch attention (number of stages completed, scores vary from 0-9), and the CLOX-I, which is an executive function task that requires goal selection, selective attention, and the self-monitoring (scores vary from 0-15, with lower scores indicating greater impairment) (Royall, Cordes, & Polk, 1998 ) . Two measures of planning were used, the Key Search and Zoo Map from the BADS.
Problem solving. This was assessed using the D-KEFS, Tower Task (number of towers completed in the minimum number of moves, maximum score = 9). The D-KEFS Tower Task is an updated version of the Tower of Hanoi Task. Problem solving was also assessed using the Matrix Reasoning subtest from the WASI and the Stockings of Cambridge (SOCs) from the CANTAB (number of towers completed in the minimum number of moves, maximum score = 12). The SOCs is a computerized version of the Tower of London task.
Working memory/attention. This was assessed using letter number sequencing, Digits Forward and Reversed, from the WMS-III, Spatial Span (maximum sequences correctly recalled, 0-9) from the CANTAB, and the Daneman and Carpenter Reading Span test (Daneman & Carpenter, 1980) (scores range, 1-6).
Speed of processing. This was evaluated using word naming and color naming from the D-KEFS Color-Word interference test.
Memory/learning. This was assessed with the WMS-III, Paired Associates, and Logical Memory, immediate and delayed, and the Auditory Recall Index. The Rey Osterrieth Figure (ROF) recall after 3 and 30 minutes was also used as a measure of memory ability. All three parts of the ROF are rated the same (range 0-36, with higher scores indicating more accurate performance; Spreen & Strauss, 1998 ) .
Visuospatial/constructive skills. These skills were assessed using the Judgment of Line Orientation (JLO; Benton, Varney, & Hamsher, 1978 ) , which is a test of visuospatial ability. Scores reported for the JLO are the number of correct line pairs, with possible scores ranging from 0-30. Also included in this domain were the Rey Osterrieth Figure copy task and the CLOX-II, which is also a copying task. Both of these tasks tap into visuospatial/constructive skills. Scores for the CLOX-II vary from 0-15, with lower scores indicating greater impairment.
Data Analyses
Results for PD patients and controls were compared with t tests. To assess the magnitude of any differences between the two groups, effect sizes for cognitive impairments were generated using Cohen's d . Because of the number of comparisons, we used, a .01 signifi cance level rather than .05 to provide increased protection against Type 1 error, without unduly compromising power.
Pearson correlations were employed to assess the association between disease progression and cognitive outcomes. Pearson correlations were also used to assess the association between different measures of executive function, visuospatial ability, and memory/learning. Z scores were computed, using the control mean and standard deviation, so that comparisons could be made across tests. Multivariate analyses of covariance (MANCOVAs) were used to compare the difference between PD and control scores for a particular cognitive domain, while using other domains as covariates, and were considered signifi cant at p < 0.05.
RESULTS
Comparison of PD vs. Control Group
Results in Table 3 indicate that PD patients showed a variable pattern of defi cits when compared to the Control group. Whereas consistent evidence of defi cits was found on measures of speed of processing, individual t tests revealed defi cits on only fi ve of nine measures of executive function (Category Fluency, Category Switching, CLOX-I, and Stroop inhibition, and inhibition switching), two of the three measures of problem solving (Matrix reasoning and SOCs), two of the three measures of working memory (Reading Span Test and Spatial Span task), and two of the three measures of visuospatial ability (ROF copy and CLOX-II). There were no signifi cant differences in terms of planning ability, attention, or memory.
The original analysis was rerun, excluding the two patients who had a H & Y of 4, so that the group consisted of only patients with mild to moderate motor impairments. Because results remained substantially the same and the pattern of defi cits for the patients with PD compared to the Control group was unchanged, data for these subjects were included in the analyses reported here. Also, the observed pattern of defi cits was identical, regardless of whether raw or age-adjusted scores were used. 
Effect Sizes
Correlations Between Cognitive Measures
Correlations between cognitive measures are shown in Table  4 . All within-domain correlations were signifi cantly positive for problem solving, working memory/attention, speed of vvvprocessing, memory and learning, and visuospatial ability, and for 8 of 10 cases for executive function. To further examine the relationship between each of the domains, scores for each of the measures in the matrix were transformed to z scores. These z scores were generated using the mean and standard deviation of the Control group. Overall scores were then produced separately for each of the fi ve domains by averaging the z scores for measures that differentiated PD patients from the Control group ( p < .01). Because of the high correlation between CLOX-I and CLOX-II, the CLOX-I was not included in the executive function domain. The sixth domain, memory/learning, was included in the matrix for the purpose 
MANCOVA
Multivariate analyses of covariance (MANCOVAs) were used to control for the effects of anticholinergic medication, memory/learning, and visuospatial ability, while assessing the difference between the PD group and the Control group on the domains of executive function, problem solving, working memory, and speed of processing. Results are shown in Table 5 . Although the differences remained significant for executive function, working memory, and speed of processing ( p < .01), defi cits in problem solving were no longer signifi cant after controlling for visuospatial ability. However, differences between the two groups remained signifi cant ( p < .01) for all domains, after controlling for memory/learning. MANCOVAs were used separately to control for the effects of anticholinergic medication, executive function, problem solving, working memory, and speed of processing ( Table 6 ). There were no signifi cant differences between the PD and Control groups for the memory/learning domain. In terms of visuospatial ability, the PD group remained signifi cantly different from controls regardless of which covariate was entered into the analysis.
DISCUSSION
We found clear signifi cant differences in performance between PD and Control groups across different subcomponents of executive functioning (working memory, problem solving, verbal fl uency, inhibition) and on tests of speed of processing and visuospatial skills. However, the groups did not differ signifi cantly on measures of planning, attention, and memory/learning. Of particular interest was the fi nding that PD patients did not show defi cits for all subcomponents of executive functioning; instead, there was evidence of variable performance. Our fi nding of a pattern of impaired and spared function is consistent with previous studies (Marinus et al., 2003 ; Muslimovic, et al., 2005 ; Uekermann et al., 2004 ; Weintraub & Stern, 2005 ) and points to a need for specifi city when assessing executive dysfunction in PD. We also examined the relationship between anticholinergic medication use and subcomponents of executive functioning and visuospatial ability and memory/learning, and found evidence that defi cits in speed of processing and visuospatial ability were independent of aspects of executive function. Moreover, we found that problem-solving defi cits were only evident for tasks with a high visuospatial content, and were no longer signifi cant when visuospatial skills were controlled for. The addition of anticholinergic medication use as a covariate did not signifi cantly change the relationship found for the different subcomponents of executive function, visuospatial ability, or memory and learning, for PD versus controls.
The profi le of executive function, speed of processing, and visuospatial defi cits reported here is similar to other recent research regarding cognitive outcomes for PD patients, regardless of disease severity. For example, two recent studies, one examining outcomes for newly-diagnosed patients and the other for advanced PD (Muslimovic et al., 2005 ; Woods & Troster, 2003 ) , reported a similar range of executive, speed of processing, and visuospatial defi cits to those found here, even though the present study was based on a sample of patients that varied widely in terms of disease severity and duration. Indeed, it has been suggested that deficits in executive function, speed of processing, and visuospatial ability appear to constitute the core defi cits for PD. By contrast, defi cits in general memory, planning, and attention are much more variable and depend on the methodology of the study and inclusion criteria.
One of our most notable fi ndings was that defi cits in speed of processing and visuospatial ability were independent of executive function, and that problem solving was not impaired when visuospatial ability was controlled for. Defi cits in visuospatial function have previously been identifi ed in PD patients without dementia (Waterfall & Crowe, 1995 ) . However, results for visuospatial defi cits have been inconsistent, and the exact cause of these defi cits remains unresolved. Whereas some researchers have argued that visuospatial deficits in PD are associated with fronto-striatal circuits and refl ect executive functioning impairment (Bondi, Kaszniak, Bayles, & Vance, 1993 ) , others have noted that PD is associated with visuospatial and problem-solving defi cits independent of executive functions (Cronin-Golomb & Braun, 1997 ) , suggesting a different pathoanatomy. In the present study, PD patients showed visuospatial defi cits that were independent of executive function defi cits. Moreover, we found that visuospatial defi cits could account for defi cits in problem-solving ability. Both these fi ndings provide evidence for cognitive defi cits unrelated to a fronto-striatal deterioration. Our results are consistent with recent reviews on the neuroanatomy of PD. These reviews have suggested that attributing the complex cognitive decline associated with PD entirely to depletion of dopamine in the basal ganglia, and subsequent deterioration of fronto-striatal circuits, is an oversimplifi cation. Instead, disease progression is more likely to be characterized by depletion of a range of neurotransmitter systems (Bohnen & Albin, 2009 ; Bohnen et al., 2006 ; Braak & Braak, 2000 ; Cools, 2006 ; Owen, 2004 ) . For example, recent imaging literature has found an association between the cholinergic system and executive defi cits (Bohnen et al., 2006 ) and posterior metabolic changes with multiple mild cognitive impairments (Huang et al., 2008 ) . Moreover, these changes have been suggested as occurring early in the disease process (Bohnen & Albin, 2009 ) . The majority of patients in this study were in the mild to moderate range in terms of disease symptoms. However, two of our patients had more severe motor problems. Despite this, correlations revealed few associations between cognitive performance and disease duration or motor symptoms. Furthermore, motor symptoms and disease duration have been reported by a number of groups as an unreliable means of identifying patients who have cognitive problems (Aarsland, Ballard, Larsen, & McKeith, 2001 ; Graham & Sagar, 1999 ; Janvin, Aarsland, Larsen, & Hugdahl, 2003 ; Lewis et al., 2005 ; Muslimovic et al., 2005 ) .
One of the strengths of this study is that a range of measures was used to identify the profi le of impaired and spared executive functions. Although there is considerable debate regarding which tests are most appropriate to measure each of the different cognitive domains (Taylor & Saint-Cyr, 1995 ) , our selection of tests and domains was theoretically motivated and based on previous research to allow comparisons (Muslimovic et al., 2005 ) . One limitation of our study was that not all measures could be corrected for age and education. However, the impact of this was minimized by ensuring that the PD group was similar to the Control group in terms of age and education. Another limitation of the study was an increased likelihood of Type 1 error due to the relatively large number of comparisons that were made. However, we attempted to compensate for this by using a more stringent test of signifi cance ( p < .01).
A number of issues were raised by this study that may warrant further consideration. First, defi cits in executive function in PD have often been assessed as though this were a unitary process, without consideration to different subcomponents (Salthouse, 2005 ) . Furthermore, much of what we know regarding defi cits in the subcomponents of executive function has come from studies that have examined single aspects of this skill with different groups of individuals. Very few studies have examined the constellation of executive function defi cits within a single group of subjects. Second, in this study, not all measures within a domain showed impairment. For example, patients showed no defi cit on the D-KEFS Tower of Hanoi, but did show defi cits on the CANTAB SOCs, a computerized version of the Tower of London. However, there is growing evidence that although these two tasks are often used interchangeably, they tap into different skills (McKinlay et al., 2009 ; McKinlay et al., 2008b ; Welsh, Revilla, Strongin, & Kepler, 2000 ) . As pointed out by Riedel and colleagues ( 2008 ) , estimates of cognitive impairment within-domain are largely dependent on the measure used to assess them. The heterogeneity of tasks employed, the varying levels of complexity, the processing demands of the different tasks (Brown & Marsden, 1990 ) , and way in which different cognitive skills are operationalized (Taylor & Saint-Cyr, 1995 ) , have all been suggested as contributing to controversy regarding the cognitive impairments associated with PD.
Identifying the profi le of cognitive defi cits specifi c to PD is important as it provides information to clinicians regarding which measures are most appropriate to identify patients who may be experiencing cognitive decline. Information regarding such individuals can be used by clinicians to target intervention strategies. For example, recent research has demonstrated that cognitive training is able to improve executive functioning for PD patients (Sammer, Reuter, Hullmann, Kaps, & Vaitl, 2006 ) and is also effective in reinforcing cognitive strategies designed to compensate for declines in functioning (Sinforiani, Banchier, Zucchella, Pacchetti, & Sandrini, 2004 ) . Information regarding intact skills is also useful because it may provide an opportunity to develop interventions that take advantage of those aspects of cognitive functioning that have been spared (Witt et al., 2006 ) . Given the effectiveness of cognitive interventions for PD patients in early stages of cognitive decline, future research should focus on developing guidelines for clinicians regarding tests that are most sensitive to identify patients who may benefi t from these therapeutic interventions.
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